These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29978754)

  • 41. Next-Generation Bruton Tyrosine Kinase Inhibitors.
    Stephens DM; Byrd JC
    J Clin Oncol; 2020 Sep; 38(25):2937-2940. PubMed ID: 32673168
    [No Abstract]   [Full Text] [Related]  

  • 42. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy.
    Jamroziak K; Tadmor T; Robak T; Polliack A
    Leuk Lymphoma; 2015 Jul; 56(7):1949-58. PubMed ID: 25356923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
    Hanna KS; Campbell M; Husak A; Sturm S
    J Oncol Pharm Pract; 2020 Jul; 26(5):1190-1199. PubMed ID: 32279595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia.
    Gianfelici V; Levato L; Molica S
    Curr Hematol Malig Rep; 2020 Aug; 15(4):343-349. PubMed ID: 32500413
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeted Therapy in Chronic Lymphocytic Leukemia.
    Kipps TJ; Choi MY
    Cancer J; 2019; 25(6):378-385. PubMed ID: 31764118
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
    Chanas-Larue A; Villalpando-Rodriguez GE; Henson ES; Johnston JB; Gibson SB
    Leuk Res; 2020 Sep; 96():106423. PubMed ID: 32712432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
    Chong EA; Roeker LE; Shadman M; Davids MS; Schuster SJ; Mato AR
    Clin Cancer Res; 2020 Jul; 26(14):3514-3516. PubMed ID: 32345646
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
    Dasanu CA
    J Oncol Pharm Pract; 2019 Jun; 25(4):1003-1005. PubMed ID: 29720040
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Second generation BTK inhibitors impair the anti-fungal response of macrophages and neutrophils.
    Colado A; Marín Franco JL; Elías EE; Amondarain M; Vergara Rubio M; Sarapura Martínez V; Cordini G; Fuentes F; Balboa L; Fernandez Grecco H; Pavlovsky M; Bezares F; Morande P; Giordano M; Gamberale R; Borge M
    Am J Hematol; 2020 Jul; 95(7):E174-E178. PubMed ID: 32267009
    [No Abstract]   [Full Text] [Related]  

  • 54. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
    Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
    JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hodgkin lymphoma transformation of chronic lymphocytic leukemia: cases report and discussion.
    Kaźmierczak M; Kroll-Balcerzak R; Balcerzak A; Czechowska E; Gil L; Sawiński K; Szczepaniak A; Komarnicki M
    Med Oncol; 2014 Jan; 31(1):800. PubMed ID: 24338339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Orelabrutinib: First Approval.
    Dhillon S
    Drugs; 2021 Mar; 81(4):503-507. PubMed ID: 33704654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
    Lutz M; Schulze AB; Rebber E; Wiebe S; Zoubi T; Grauer OM; Keßler T; Kerkhoff A; Lenz G; Berdel WE
    Cancer Res Treat; 2017 Apr; 49(2):548-552. PubMed ID: 27456945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Richter syndrome: chronic lymphocytic leukemia transformation into Hodgkin's disease.
    Zavdy O; Twig G; Kneller A; Yaniv G; Davidson T; Schiby G; Amital H
    Isr Med Assoc J; 2013 Oct; 15(10):650-1. PubMed ID: 24266095
    [No Abstract]   [Full Text] [Related]  

  • 59. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
    Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
    Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.